1. 325PAssociation between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. (24th November 2019) Authors: Wong, L; Ang, A; Ng, K; Tan, S H; Choo, S P; Tai, D; Lee, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 430PPhase I study: Safety and tolerability of varlitinib (VAR) in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours. (23rd October 2018) Authors: Seet, A; Choo, S P; Tai, D W M; Lam, Y C J; Teng, W T; Lim, C; Lim, T K H; Tan, I B; Petricoin, E; Ng, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 64P Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?. (15th December 2019) Authors: Lee, J; Ng, K; Wong, L; Ang, A; Tan, S H; Tai, D; Choo, S P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗